Gainers

• Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million.
• TransMedics Group (NASDAQ:TMDX) shares rose 23.73% to $85.36. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3 earnings report came out yesterday.
• CryoPort (NASDAQ:CYRX) shares moved upwards by 20.68% to $19.37. The market value of their outstanding shares is at $812.9 million. As per the press release, Q3 earnings came out yesterday.
• Dogwood Therapeutics (NASDAQ:DWTX) shares increased by 20.67% to $1.25. The company's market cap stands at $39.7 million. As per the news, the Q3 earnings report came out yesterday.
• Fulgent Genetics (NASDAQ:FLGT) shares moved upwards by 19.48% to $22.3. The market value of their outstanding shares is at $576.8 million. The company's, Q3 earnings came out yesterday.
• CG Oncology (NASDAQ:CGON) stock rose 19.02% to $77.12. The market value of their outstanding shares is at $5.7 billion. The company's, Q3 earnings came out today.

Losers

• AirSculpt Technologies (NASDAQ:AIRS) stock fell 57.8% to $0.61 during Friday's regular session. The market value of their outstanding shares is at $103.8 million. As per the news, the Q3 earnings report came out today.
• Biodesix (NASDAQ:BDSX) shares declined by 50.41% to $9.84. The market value of their outstanding shares is at $205.4 million. As per the press release, Q3 earnings came out yesterday.
• Baird Medical Investment (NASDAQ:BDMD) shares declined by 44.9% to $0.09. The company's market cap stands at $5.0 million.
• CVRx (NASDAQ:CVRX) stock declined by 42.76% to $0.84. The company's market cap stands at $39.0 million. As per the news, the Q3 earnings report came out yesterday.
• Virax Biolabs Group (NASDAQ:VRAX) shares declined by 38.23% to $0.73.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) shares fell 34.89% to $0.14. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.